Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.

Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, Le Quan Sang KH, Dickson P, Harmatz P, Phillips J, Owen N, Cherukuri A, Jayaram K, Jeha GS, Larimore K, Chan ML, Huntsman Labed A, Day J, Hoover-Fong J.

N Engl J Med. 2019 Jul 4;381(1):25-35. doi: 10.1056/NEJMoa1813446. Epub 2019 Jun 18.


Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity.

Larimore K, Nguyen T, Badillo B, Lau K, Zori R, Shepherd G, Zoog SJ, Weng HH, Gupta S.

J Immunol Methods. 2019 May;468:20-28. doi: 10.1016/j.jim.2019.03.004. Epub 2019 Mar 14.


Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.

Gupta S, Lau K, Harding CO, Shepherd G, Boyer R, Atkinson JP, Knight V, Olbertz J, Larimore K, Gu Z, Li M, Rosen O, Zoog SJ, Weng HH, Schweighardt B.

EBioMedicine. 2018 Nov;37:366-373. doi: 10.1016/j.ebiom.2018.10.038. Epub 2018 Oct 23.


Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.

Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, Li M, Schweighardt B, Larimore K, Longo N.

Mol Genet Metab. 2018 Nov;125(3):217-227. doi: 10.1016/j.ymgme.2018.06.010. Epub 2018 Aug 23.


Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.

Longo N, Zori R, Wasserstein MP, Vockley J, Burton BK, Decker C, Li M, Lau K, Jiang J, Larimore K, Thomas JA.

Orphanet J Rare Dis. 2018 Jul 4;13(1):108. doi: 10.1186/s13023-018-0858-7.


Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).

Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J, Merilainen M, Jiang J, Larimore K, Gupta S, Gu Z, Northrup H; PRISM investigators.

Mol Genet Metab. 2018 May;124(1):27-38. doi: 10.1016/j.ymgme.2018.03.006. Epub 2018 Mar 31.


Interferon-driven deletion of antiviral B cells at the onset of chronic infection.

Fallet B, Narr K, Ertuna YI, Remy M, Sommerstein R, Cornille K, Kreutzfeldt M, Page N, Zimmer G, Geier F, Straub T, Pircher H, Larimore K, Greenberg PD, Merkler D, Pinschewer DD.

Sci Immunol. 2016 Oct 21;1(4). pii: eaah6817. doi: 10.1126/sciimmunol.aah6817.


Inflammatory monocytes hinder antiviral B cell responses.

Sammicheli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C, Maganuco CG, Fallet B, Ganzer L, Sironi L, Mainetti M, Ostuni R, Larimore K, Greenberg PD, de la Torre JC, Guidotti LG, Iannacone M.

Sci Immunol. 2016 Oct 21;1(4). pii: eaah6789.


Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, Bradley T, Pemble CW 4th, Zhang J, Gao F, Montefiori DC, Bouton-Verville H, Kelsoe G, Larimore K, Greenberg PD, Parks R, Foulger A, Peel JN, Luo K, Lu X, Trama AM, Vandergrift N, Tomaras GD, Kepler TB, Moody MA, Liao HX, Haynes BF.

Sci Transl Med. 2016 Apr 27;8(336):336ra62. doi: 10.1126/scitranslmed.aaf0618.


Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.

Waldschmidt HV, Homan KT, Cruz-Rodríguez O, Cato MC, Waninger-Saroni J, Larimore KM, Cannavo A, Song J, Cheung JY, Kirchhoff PD, Koch WJ, Tesmer JJ, Larsen SD.

J Med Chem. 2016 Apr 28;59(8):3793-807. doi: 10.1021/acs.jmedchem.5b02000. Epub 2016 Apr 13.


Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10.

Finton KA, Friend D, Jaffe J, Gewe M, Holmes MA, Larman HB, Stuart A, Larimore K, Greenberg PD, Elledge SJ, Stamatatos L, Strong RK.

PLoS Pathog. 2014 Sep 25;10(9):e1004403. doi: 10.1371/journal.ppat.1004403. eCollection 2014 Sep.


Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitors.

Homan KT, Larimore KM, Elkins JM, Szklarz M, Knapp S, Tesmer JJ.

ACS Chem Biol. 2015 Jan 16;10(1):310-9. doi: 10.1021/cb5006323. Epub 2014 Oct 3.


SC*994C>T causes the Sc(null) phenotype in Pacific Islanders and successful transfusion of Sc3+ blood to a patient with anti-Sc3.

Reid ME, Hue-Roye K, Velliquette RW, Larimore K, Moscarelli S, Ohswaldt N, Lomas-Francis C.

Immunohematology. 2013;29(2):69-72.


Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.

Finton KA, Larimore K, Larman HB, Friend D, Correnti C, Rupert PB, Elledge SJ, Greenberg PD, Strong RK.

PLoS Pathog. 2013;9(9):e1003639. doi: 10.1371/journal.ppat.1003639. Epub 2013 Sep 26.


Molecular background of RH in Bastiaan, the RH:-31,-34 index case, and two novel RHD alleles.

Reid ME, Hipsky CH, Velliquette RW, Lomas-Francis C, Larimore K, Olsen C.

Immunohematology. 2012;28(3):97-103.


Shaping of human germline IgH repertoires revealed by deep sequencing.

Larimore K, McCormick MW, Robins HS, Greenberg PD.

J Immunol. 2012 Sep 15;189(6):3221-30. doi: 10.4049/jimmunol.1201303. Epub 2012 Aug 3. Erratum in: J Immunol. 2014 Jan 1;192(1):534.


B7h-expressing dendritic cells and plasma B cells mediate distinct outcomes of ICOS costimulation in T cell-dependent antibody responses.

Larimore K, Liang L, Bakkour S, Sha WC.

BMC Immunol. 2012 Jun 11;13:29. doi: 10.1186/1471-2172-13-29.


Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.

Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP.

Science. 2008 Jan 11;319(5860):215-20. doi: 10.1126/science.1148886.


A case report: cold hemagglutinin disease in a pancreatic and renal transplant patient.

Beiting CY, Larimore KS.

Immunohematology. 1988;4(4):85-7.


Supplemental Content

Loading ...
Support Center